Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report

Genitourinary Cancer

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report

Am J Case Rep.

Prelaj A, Rebuzzi SE, Magliocca FM, Speranza I, Corongiu E, Borgoni G, Perugia G, Liberti M, Bianco V.

doi: 10.12659/AJCR.896989

Leukemia

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

N Engl J Med.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H

doi: 10.1056/NEJMoa1614359.

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Genitourinary CancerRadio-Oncology

Primary follicular dendritic cell sarcoma of the urinary bladder: the first case report and potential diagnostic pitfalls

Diagn Pathol.

Duan GJ, Wu YL, Sun H, Lang L, Chen ZW, Yan XC

doi: 10.1186/s13000-017-0625-4.

Genitourinary Cancer

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Clin Genitourin Cancer.

Robinson AG, Wei X, Vera-Badillo FE, Mackillop WJ, Booth CM

doi: 10.1016/j.clgc.2016.12.025.

RECOMMENDED

Genitourinary Cancer

[Unusual Cause of Acute Kidney Failure in a Patient with Metastatic Bladder Carcinoma Undergoing Palliative Chemotherapy]

★ 1 Recommended by Alexander Meisel, Faculty Member

Praxis (Bern 1994).

Müller J, Kalbermatten Magaya N, Traichel B, Taverna C

doi: 10.1024/1661-8157/a003527.Visit the original publication at ncbi.nlm.nih.gov

Leukemia

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia

Pediatr Blood Cancer.

Mayfield JR, Czuchlewski DR, Gale JM, Matlawska-Wasowska K, Vasef MA, Nickl C, Pickett G, Ness SA, Winter SS

doi: 10.1002/pbc.26328.

Genitourinary Cancer

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer

Eur Urol.

Christensen E, Birkenkamp-Demtröder K, Nordentoft I, Høyer S, van der Keur K, van Kessel K, Zwarthoff E, Agerbæk M, Ørntoft TF, Jensen JB, Dyrskjøt L

doi: 10.1016/

Gynecologic Cancer

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncol.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators

doi: 10.1016/

Related content

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Primary follicular dendritic cell sarcoma of the urinary bladder: the first case report and potential diagnostic pitfalls

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

[Unusual Cause of Acute Kidney Failure in a Patient with Metastatic Bladder Carcinoma Undergoing Palliative Chemotherapy]

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial